atezolizumab
roche
['immotion010', 'improve ', 'renal,(-adrenal)', 'atezo', 'medsir']
dr. axel bex shares analysis from phase 3 immotion010 trial. atezolizumab as adjuvant therapy in pts with renal cell carcinoma and increased risk of recurrence after resection, did not improve clinical outcomes vs placebo (dfs was 57.2 mo for atezo vs 49.5 mo for pbo).
#esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM